Longboard Pharmaceuticals Inc LBPH:NASDAQ

RT Quote | NASDAQ | USD
Last | 05/14/21 EDT
8.29quote price arrow down-0.47 (-5.37%)
Volume
34,589
52 week range
7.98 - 18.95

...

Loading . . .
  • Open8.75
  • Day High9.00
  • Day Low7.98
  • Prev Close8.29
  • 52 Week High18.95
  • 52 Week High Date04/06/21
  • 52 Week Low7.98
  • 52 Week Low Date05/14/21

Key Stats

  • Market Cap142.75M
  • Shares Out17.22M
  • 10 Day Average Volume0.03M
  • Dividend-
  • Dividend Yield-
  • Beta
  • YTD % Change-

KEY STATS

  • Open8.75
  • Day High9.00
  • Day Low7.98
  • Prev Close8.29
  • 52 Week High18.95
  • 52 Week High Date04/06/21
  • 52 Week Low7.98
  • 52 Week Low Date05/14/21
  • Market Cap142.75M
  • Shares Out17.22M
  • 10 Day Average Volume0.03M
  • Dividend-
  • Dividend Yield-
  • Beta
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-0.85
  • P/E (TTM)-9.74
  • Fwd P/E (NTM)-3.25
  • EBITDA (MRQ)-14.40M
  • ROE (MRQ)-
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Longboard Pharmaceuticals Inc

There is no recent news for this security.

Latest From Our Partners

There is no recent news for this security.

Profile

MORE
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines for neurological diseases. Its pipelines includes LP352, LP143 and LP659. LP352 is an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype (5-HT2c) superagonist for the treatment of developmental and epileptic encephalopathies (DEEs), including Dravet syndrome and Lennox-Gastaut syndrome, among others. LP143 is a centrally acting, full...
Kevin Lind
President
Chad Orevillo
Vice President
Address
6154 Nancy Ridge Drive
San Diego, CA
92121
United States